An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells

Cancer Science

Volumn 103, Issue 1, 2012, Pages 100-106

  Uota, Shin ^a   Zahidunnabi Dewan, Md ^b   Saitoh, Yasunori ^a   Muto, Susumu ^c   Itai, Akiko ^c   Utsunomiya, Atae ^d   Watanabe, Toshiki ^e   Yamamoto, Naoki ^f   Yamaoka, Shoji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Institute of Medicinal Molecular Design (IMMD) Inc   (Japan)

^d IMAMURA BUN IN HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE INHIBITOR; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; T CELL LEUKEMIA; TUMOR GROWTH;

ADULT; ANIMALS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CASPASES; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; I-KAPPA B KINASE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LEUKOCYTES, MONONUCLEAR; LUCIFERASES; MICE; MICE, INBRED NOD; MICE, SCID; NF-KAPPA B;

EID: 84855498896     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02110.x     Document Type: Article

References (37)

1. Hinuma Y, Nagata K, Hanaoka M et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981; 78: 6476-80.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-9.
3. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-5.
4. Okamoto T, Ohno Y, Tsugane S et al. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res 1989; 80: 191-5.
5. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989; 1: 441.
6. Osame M, Usuku K, Izumo S et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 1031-2.
7. Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-10.
8. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24: 6047-57.
9. Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M, Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci USA 1990; 87: 1071-5.
10. Akagi T, Ono H, Shimotohno K. Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood 1995; 86: 4243-9.
11. Kannagi M, Matsushita S, Harada S. Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell-leukemia cells. Int J Cancer 1993; 54: 582-8.
12. Kinoshita T, Shimoyama M, Tobinai K et al. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 5620-4.
13. Furukawa Y, Kubota R, Tara M, Izumo S, Osame M. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001; 97: 987-93.
14. Tamiya S, Matsuoka M, Etoh K et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996; 88: 3065-73.
15. Mori N, Fujii M, Ikeda S et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999; 93: 2360-8.
16. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010; 2: a000109.
17. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
18. Hironaka N, Mochida K, Mori N, Maeda M, Yamamoto N, Yamaoka S. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 2004; 6: 266-78.
19. Dewan MZ, Uchihara JN, Terashima K et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006; 107: 716-24.
20. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
21. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1: a000034.
22. Onai Y, Suzuki J, Kakuta T et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 2004; 63: 51-9.
23. Tanaka A, Konno M, Muto S et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324-31.
24. Ochiai T, Saito Y, Saitoh T et al. Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells. J Med Dent Sci 2008; 55: 49-59.
25. Nonaka M, Uota S, Saitoh Y et al. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res 2009; 315: 141-50.
26. Saitoh Y, Martinez Bruyn VJ, Uota S et al. Overexpression of NF-kappaB inducing kinase underlies constitutive NF-kappaB activation in lung cancer cells. Lung Cancer 2010; 70: 263-70.
27. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393-7.
28. Uchiyama T, Hori T, Tsudo M et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest 1985; 76: 446-53.
29. Waldmann TA, Greene WC, Sarin PS et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest 1984; 73: 1711-8.
30. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076-82.
31. Fukuda S, Horimai C, Harada K et al. Aldosterone-induced kidney injury is mediated by NFκB activation. Clin Exp Nephrol 2011; 15: 41-9.
32. Hall WW, Fujii M. Deregulation of cell-signaling pathways in HTLV-1 infection. Oncogene 2005; 24: 5965-75.
33. Horiuchi S, Yamamoto N, Dewan MZ et al. Human T-cell leukemia virus type-I Tax induces expression of interleukin-6 receptor (IL-6R): Shedding of soluble IL-6R and activation of STAT3 signaling. Int J Cancer 2006; 119: 823-30.
34. Hideshima T, Neri P, Tassone P et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006; 12: 5887-94.
35. Schon M, Wienrich BG, Kneitz S et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 2008; 100: 862-75.
36. Watanabe M, Ohsugi T, Shoda M et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005; 106: 2462-71.
37. Oh U, McCormick MJ, Datta D et al. Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I associated neurologic disease. Blood 2011; 117: 3363-9.